arrow
J

John Anderson

georgetown university
H指数:21
被引数:1,932

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis

加拉达西马布预防遗传性血管性水肿的长期综合安全性与有效性

2026-06-100
OAAI
Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension

Sebetralstat的长期安全性与有效性:KONFIDENT-S开放标签扩展研究的期中分析

2025-08-290
OAAI
Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria

抗KIT巴佐尔伏利单抗治疗慢性自发性荨麻疹

2025-05-260
OAAI
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial
2024-03-014
OAAI
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
LANCET
IF88.5
2023-04-0145
PRE
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study (vol 16, 86, 2021)
2021-07-280
OAAI
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial
2021-07-01100
OAAI
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
2021-02-1523
OAAI
Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings
2019-07-0111
OAAI
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks A Randomized Clinical Trial
2018-11-27203
OAAI
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema
2018-09-0169
OAAI